#immunomodulators
LightNews LightNews
insightrx.bsky.social
Autoimmune Inflammatory Immunomodulators Market | Share 2035 | WiseGuyReports www.wiseguyreports.com/reports/auto...
Autoimmune Inflammatory Immunomodulators Market | Share 2035
Autoimmune Inflammatory Immunomodulators Market is Estimated to Reach USD 250 Billion by 2035, Growing at a CAGR of 5.6% During 2026 - 2035 | Wiseguy Reports
www.wiseguyreports.com
October 30, 2026 at 8:08 AM
insightrx.bsky.social
Autoimmune Inflammatory Immunomodulators Market | Share 2035 | WiseGuyReports www.wiseguyreports.com/reports/auto...
Autoimmune Inflammatory Immunomodulators Market | Share 2035
Autoimmune Inflammatory Immunomodulators Market is Estimated to Reach USD 250 Billion by 2035, Growing at a CAGR of 5.6% During 2026 - 2035 | Wiseguy Reports
www.wiseguyreports.com
October 30, 2026 at 8:08 AM
papertis.bsky.social
Non-infectious uveitis.

7 studies, 992 patients: adalimumab cut treatment failure vs placebo (RR 0.67), with more injection-site reactions.

Chen, Chan et al. Pharmacotherapy 2026
https://pubmed.ncbi.nlm.nih.gov/42870312/

Weekly papers by topic, free: https://papertis.com
#MedSky #OphthoSky
Immunomodulators for non-infectious uveitis. Pharmacotherapy 2026, 7 studies, 992 participants. Treatment failure, adalimumab vs placebo: RR 0.67. Injection-site reactions: RR 2.67. Comparative safety estimates remain uncertain.
October 26, 2026 at 2:03 PM
commschem.nature.com
Just out: Precision targeting of tumor-associated macrophages via a 6-substituted pyrrolo[2,3-d]pyrimidine chimeric molecule for enhanced cancer immunotherapy
Precision targeting of tumor-associated macrophages via a 6-substituted pyrrolo[2,3-d]pyrimidine chimeric molecule for enhanced cancer immunotherapy
Communications Chemistry, Published online: 15 October 2026; doi:10.1038/s42004-026-02248-4The clinical application of small molecule immunomodulators is limited by poor selectivity for tumor-associated macrophages (TAMs) and systemic toxicities. Here, the authors develop a folate receptor-beta targeted chimeric molecule, AS-6, which selectively accumulates in TAMs, remodels the tumor microenvironment, and enhances the efficacy of anti-PD-1 therapy while reducing systemic side effects.
dlvr.it
October 15, 2026 at 2:16 PM
shakiramrfr.bsky.social
Immunomodulators Market Size, Growth, Trends, Report 2035 www.marketresearchfuture.com/reports/immu...
Immunomodulators Market Size, Growth, Trends, Report 2035
Immunomodulators Market Industry is expected to grow Billion USD to 1881.06 Billion USD by 2035, driving CAGR of 15.8% during the forecast period (2025-2035).
www.marketresearchfuture.com
October 13, 2026 at 7:25 AM
braithwaiteat.bsky.social
New paper out now in Genome Medicine! 🎉
Which in vitro model best reflects human inflammatory disease? We profiled >150K PBMCs using #scRNAseq across 11 stimuli to map intra- & intercellular responses across 21 cell subsets. 🧵👇
doi.org/10.1186/s130...
🧪🧬🖥️ #SingleCell #AcademicSky
A multi-panel figure summarizing the experimental workflow and single-cell RNA sequencing results for in vitro stimulated immune cells. The top left panel illustrates the experimental workflow, showing healthy donor PBMCs treated with immunomodulators for 48 hours, followed by cell fixation, SPLiT-Seq single-cell barcoding, RNA sequencing, and downstream comparative analysis. The bottom left panel displays a UMAP plot showing the distinct clustering of various immune cell types across myeloid and lymphoid lineages, including monocytes, B cells, T cells, and NK cells. The right panel features a grid plot comparing the responses of these specific immune cell types across 11 different stimulations. This plot highlights the mean fold change (represented by color) and the number of differentially expressed genes (represented by the size of the squares) per cell type and stimulation condition.
October 11, 2026 at 4:42 PM
braithwaiteat.bsky.social
​Which in vitro model best reflects human disease? We compared scRNA-seq profiles of >150K PBMCs across 11 stimuli, mapping them against inflammatory diseases like SLE to highlight the most clinically relevant models. Free data: doi.org/10.1186/s130... 🧪🧬🖥️ #immunosky #scRNAseq #SingleCell
A multi-panel figure summarizing the experimental workflow and single-cell RNA sequencing results for in vitro stimulated immune cells. The top left panel illustrates the experimental workflow, showing healthy donor PBMCs treated with immunomodulators for 48 hours, followed by cell fixation, SPLiT-Seq single-cell barcoding, RNA sequencing, and downstream comparative analysis. The bottom left panel displays a UMAP plot showing the distinct clustering of various immune cell types across myeloid and lymphoid lineages, including monocytes, B cells, T cells, and NK cells. The right panel features a grid plot comparing the responses of these specific immune cell types across 11 different stimulations. This plot highlights the mean fold change (represented by color) and the number of differentially expressed genes (represented by the size of the squares) per cell type and stimulation condition.
October 9, 2026 at 2:55 PM
ogredragon.bsky.social
have you doctor contact BioNtech out of Germany , a world leader in mRNA therapies, they built the Pfizer COVID Vaccine and are doing wonderful work.. www.biontech.com/us/en/home.h...
BioNTech: Advancing science to help transform cancer and infectious disease treatments
BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases.
www.biontech.com
October 3, 2026 at 5:14 AM
rheumatologyadv.bsky.social
In adults with polymyalgia rheumatica, treatment with IL-6Ri facilitates successful tapering and cessation of glucocorticoid therapy more effectively than conventional synthetic immunomodulators.

https://www.rheumatologyadvisor.com/news/il-6-inhibitors-glucocorticoid-use-polymyalgia-rheumatica/
IL-6 Inhibitors Reduce Glucocorticoid Use in Polymyalgia Rheumatica
Interleukin-6 receptor inhibitors are associated with greater reductions in glucocorticoid use among patients with polymyalgia rheumatica.
www.rheumatologyadvisor.com
October 1, 2026 at 2:36 PM
prnews.bsky.social
Dry Eye Disease Market Share, Demand & Growth by 2034

The Dry Eye Disease Market is expected to witness steady growth from 2025 to 2031, driven by the increasing prevalence of dry eye disease, growing aging populations, rising screen exposure, changing lifestyles, and advancements in ophthalmic…
Dry Eye Disease Market Share, Demand & Growth by 2034
The Dry Eye Disease Market is expected to witness steady growth from 2025 to 2031, driven by the increasing prevalence of dry eye disease, growing aging populations, rising screen exposure, changing lifestyles, and advancements in ophthalmic treatments and diagnostic technologies. The market includes therapeutic options such as artificial tears, anti-inflammatory medications, immunomodulators, and other treatments, along with diagnostic approaches used to assess tear production, tear-film stability, and ocular surface health.
www.news24.ph
October 1, 2026 at 9:04 AM
cp-trendsparasitol.bsky.social
Ancylotensins: a new category of hookworm excretory-secretory proteins
Ancylotensins: a new category of hookworm excretory-secretory proteins
Hookworms can parasitize humans for years because they export excretory-secretory proteins (ESPs) into their hosts. Four known categories of ESPs are antithrombotics, digestive enzymes, detoxifying enzymes, and immunomodulators. Koch et al. recently discovered ancylotensins, a new category of ESPs that mimic the mammalian gut hormone neurotensin.
dlvr.it
September 30, 2026 at 11:50 AM
liverpath-hphs.bsky.social
This Friday! HPHS Western Regional Session webinar:
💊DILI in the era of oncologic immunomodulators
⏱️October 2, 12 PM EDT
🌐 Zoom
🎙️Drs David Kleiner, Lily Dara, and Kwun Wen
Check your e-mail for free registration info
mailchi.mp/0250206de480...
#liverpath #liversky #pathsky
This Friday: DILI in the era of oncologic immunomodulators
mailchi.mp
September 29, 2026 at 2:11 PM
dail06.bsky.social
👉 What medicines are used to treat Crohn’s disease?
👉 Which types of drugs may be part of Crohn’s disease management? 👉 Full medical explanation here:

healthuseful.com/crohns-disea...

#CrohnsDisease #IBD #CrohnsTreatment #HealthEducation
Crohn’s Disease Drugs
Learn about Crohn’s disease drugs, including biologics, steroids, immunomodulators, antibiotics, and newer targeted medicines.
healthuseful.com
September 28, 2026 at 4:49 AM
currentmedscience.bsky.social
#mRNAVaccines hold promise in #Oncology.

This review highlights RNA design, lipid nanoparticle delivery, antigen encoding, and immunomodulators as strategies to overcome TME barriers in cancer #immunotherapy. #medsky

To read: doi.org/10.1007/s115...

#currentmedicalscience
Development of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization
September 27, 2026 at 1:15 PM
pritimrfr.bsky.social
Immunomodulators Market Size, Growth, Trends, Report 2035 www.marketresearchfuture.com/reports/immu...
www.marketresearchfuture.com
September 17, 2026 at 6:09 AM
y-ogita.bsky.social
1 new message www.marketresearchfuture.com/reports/immu...
Immunomodulators Market Size, Share & Growth Report 2035 | MRFR
The Immunomodulators market is projected to grow from USD Billion 374.56 in 2024 to USD Billion 1881.06 by 2035, at a CAGR of 15.8% during 2025-2035.
www.marketresearchfuture.com
September 17, 2026 at 6:19 AM
y-ogita.bsky.social
Immunomodulators Market Size, Growth, Trends, Report 2035 www.marketresearchfuture.com/reports/immu...
www.marketresearchfuture.com
September 9, 2026 at 10:36 AM
y-ogita.bsky.social
Immunomodulators Market Size, Growth, Trends, Report 2035 www.marketresearchfuture.com/reports/immu...
Immunomodulators Market Size, Share & Growth Report 2035 | MRFR
The Immunomodulators market is projected to grow from USD Billion 374.56 in 2024 to USD Billion 1881.06 by 2035, at a CAGR of 15.8% during 2025-2035.
www.marketresearchfuture.com
September 9, 2026 at 10:20 AM
valebodi.bsky.social
Furthermore, ME/CFS-associated genes were mapped to compounds in drug databases as possible treatments for further investigation. In muscle gene expression data, 107 approved compounds target 26 genes with functions relevant to mitochondrial support and immunomodulators. From the DecodeME GWAS, 83
September 7, 2026 at 10:33 PM
matthieuholub.bsky.social
Risk Stratification for Tuberculosis Reactivation in Patients Receiving Biological and Non-biological Immunomodulators: A Review of Current Literature - Journal of Infection www.journalofinfection.com/article/S016...
Risk Stratification for Tuberculosis Reactivation in Patients Receiving Biological and Non-biological Immunomodulators: A Review of Current Literature
Tuberculosis (TB) is a critical global health concern, with about one-quarter of the world's population having an immune response against Mycobacterium tuberculosis (MTB). These individuals are at ris...
www.journalofinfection.com
September 7, 2026 at 6:15 AM
biorxiv-immuno.bsky.social
Evolutionary adaptation of helminth immunomodulators to their hosts https://www.biorxiv.org/content/10.64898/2026.09.02.748793v1
September 4, 2026 at 11:16 PM
biorxivpreprint.bsky.social
Evolutionary adaptation of helminth immunomodulators to their hosts https://www.biorxiv.org/content/10.64898/2026.09.02.748793v1
September 4, 2026 at 11:16 PM
vakarias.bsky.social
Glad to see RESILIENCE doing more investigation. Definitely a big supporter for trying this over the DOD’s recent 8 million dollar investment in hydroxychloroquine studies… there is merit in immunomodulators but their drug combo choice, Pemgarda, doesn’t reduce fragmented viral protein replication
September 5, 2026 at 12:00 AM
Immunomodulators Market Size, Growth, Trends, Report 2035 www.marketresearchfuture.com/reports/immu...
Immunomodulators Market Size, Share & Growth Report 2035 | MRFR
The Immunomodulators market is projected to grow from USD Billion 374.56 in 2024 to USD Billion 1881.06 by 2035, at a CAGR of 15.8% during 2025-2035.
www.marketresearchfuture.com
September 1, 2026 at 9:03 AM
Immunomodulators Market Size, Growth, Trends, Report 2035 www.marketresearchfuture.com/reports/immu...
Immunomodulators Market Size, Share & Growth Report 2035 | MRFR
The Immunomodulators market is projected to grow from USD Billion 374.56 in 2024 to USD Billion 1881.06 by 2035, at a CAGR of 15.8% during 2025-2035.
www.marketresearchfuture.com
September 1, 2026 at 9:10 AM